Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Retained Earnings (2016 - 2025)

CytomX Therapeutics' Retained Earnings history spans 12 years, with the latest figure at $111000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.02% year-over-year to $111000.0; the TTM value through Dec 2025 reached $111000.0, up 100.02%, while the annual FY2025 figure was $111000.0, 100.02% up from the prior year.
  • Retained Earnings reached $111000.0 in Q4 2025 per CTMX's latest filing, up from $104000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $111000.0 in Q4 2025 to a low of -$723.4 million in Q4 2023.
  • Average Retained Earnings over 5 years is -$462.8 million, with a median of -$639.6 million recorded in 2021.
  • The largest YoY upside for Retained Earnings was 163.49% in 2024 against a maximum downside of 2729550.0% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$623.6 million in 2021, then decreased by 15.93% to -$722.9 million in 2022, then dropped by 0.08% to -$723.4 million in 2023, then rose by 4.41% to -$691.6 million in 2024, then skyrocketed by 100.02% to $111000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Retained Earnings are $111000.0 (Q4 2025), $104000.0 (Q3 2025), and -$668.2 million (Q2 2025).